Skip to content

Author

D. Rodríguez-Abreu

5 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world treatment pathways and outcomes in metastatic NSCLC across Spanish hospitals: Insights from the ECO-ARWEN study.

716 Background: Real-world evidence can help evaluate whether advances in oncology care are being consistently translated into routine clinical practice. The rapid evolution of immunotherapy and targeted therapies has reshaped the management of metastatic non-small cell lung cancer (mNSCLC). However, the extent...

Á. Rogado, Rocio Casado, C. Camps et al. · 0 citations
Aug 2026

Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.

BACKGROUND Adding perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved survival outcomes compared with neoadjuvant chemotherapy and surgery alone in participants with early-stage non-small-cell lung cancer (NSCLC) in the phase 3, randomized KEYNOTE-671 study. We report results from KEYNOTE-671...

H. Wakelee, J. Spicer, S. Gao et al. · 1 citation
Review Open access Oct 2026

Real-World First-Line Treatment Characteristics and Physician Drivers in Advanced/Metastatic Non-Small Cell Lung Cancer, PD-L1 ≥ 50%, and without Actionable Genomic Alterations.

INTRODUCTION For patients with advanced/metastatic non-small cell lung cancer (aNSCLC) without actionable genomic alterations (AGAs) and with programmed death-ligand 1 (PD-L1) ≥ 50%, first-line (1L) treatment options include immunotherapy (IO) monotherapy or IO with chemotherapy. However, real-world data describing tre...

D. Owen, Martin Sebastian, H. Kenmotsu et al. · 0 citations
Clinical trial Sep 2026

Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial.

This study aimed to assess the efficacy and safety of ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated NSCLC whose disease progressed after third-generation EGFR tyrosine kinase inhibitor (TKI) therapy.

X. Le, A. Passaro, Yuan-Yuan Zhao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.